FDA warned Dr. David Lubeck for running a combination-drug study without an IND and enrolling five subjects.
What happened
FDA inspected the clinical site from April 12 to April 20, 2022, under its Bioresearch Monitoring Program. FDA found that Dr. Lubeck, as sponsor-investigator, began a study of an investigational combination product without submitting or having an IND in effect, and five human subjects were enrolled. FDA also found his May 10, 2022 response inadequate because the IND he later submitted covered a different protocol.
What FDA found
He began a clinical investigation of investigational drugs without submitting an IND.
21 CFR 312.20(a), 312.20(b)He did not have an IND in effect before starting the study.
21 CFR 312.40(a)The study did not qualify for an IND exemption.
21 CFR 312.2He enrolled five subjects and gave study drug without an IND covering the protocol.
21 CFR 312.40The IND he later submitted covered a different protocol, not the study he started.
21 CFR 312.40His response did not include a corrective action plan for deciding when an IND is required.
21 CFR 312.2
What FDA wants
Within 15 business days, FDA asks Dr. Lubeck to notify the office in writing of actions taken to prevent similar violations and to provide a corrective action plan for deciding when an IND is required and complying with IND rules.
Who should pay attention
- sponsor-investigators running investigator-initiated trials
- IRBs reviewing combination-product studies
- clinical research sites and study staff
This is a summary. Read the original letter on fda.gov.